Most Read Articles
Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

2 days ago
Case presentation: The patient is a 46-year-old Korean lady who first presented with aggravating pleuritic chest pain characterised by a stabbing pain in the chest when inhaling and exhaling. A diagnosis of non-small cell lung cancer (NSCLC) was made from computed tomography (CT)-guided needle aspiration biopsy, and the tumour was found to be epidermal growth factor receptor (EGFR) mutation-positive (exon 19 deletion). Chest imaging revealed the presence of left-sided pleural seeding nodules. The patient was treated with afatanib with partial response as best response. Ten months after starting treatment, the patient experienced disease progression.

Liquid biopsy promising for multidrug resistance detection in multiple myeloma

Jairia Dela Cruz
04 May 2020

Liquid biopsy may facilitate detection and serial monitoring of multidrug resistance (MDR) in multiple myeloma by analysing multiparticles (MPs) in blood samples of patients, with a recent study showing that MDR markers are found on MPs of stem-cell-like origin.

“One of the most important mechanisms by which cancers acquire MDR is through the overexpression of resistance proteins, belonging to the ATP class of drug transporters, including P-glycoprotein (P-gp). These are plasma membrane drug efflux transporters that mediate the removal of chemotherapeutics from the cancer cell plasma membrane,” researchers said. [Int J Mol Sci 2017;18:2362]

“We discovered that cancer-derived MPs confer the transfer and spread of MDR within cancer cell populations through the intercellular transfer of functional resistance proteins and nucleic acids packaged within the vesicular cargo,” they added. [Pharmacol Res 2013;76:77-83; Mol Cancer 2012;11:37; Leukemia 2009;23:1643-1649]

In the current study, the researchers immunophenotyped MPs (or circulating large extracellular vesicles) isolated from patients for the presence of four protein biomarkers useful for monitoring MDR development, disease burden and disease progression in multiple myeloma. These biomarkers were the MDR protein P-gp, the plasma-cell marker CD138, the stem-cell marker CD34, and the MP marker and mediator of cancer spread phosphatidylserine (PS).

Three markers (P-gp, CD138, PS) were evaluated independently in 74 patients, among whom 42 were treatment responsive (partial remission, n=30; complete remission, n=12), 14 had de novo disease and 18 had a relapse. The complete signature comprising four markers (P-gp, CD138, PS, CD34) was assessed in 11 patients.

Results revealed that elevated levels of P-gp+ and PS+ MPs were associated with disease progression and treatment unresponsiveness. P-gp, PS and CD34 proteins were predominantly expressed in CD138 MPs in advanced disease. Of note, a dual-positive (CD138P-gp+CD34+) MP was elevated in aggressive/unresponsive disease. [Blood Cancer J 2020;10:37]

“In conclusion, MPs provide a surrogate marker of their cells of origin, which in the case of myeloma are predominantly confined to the bone marrow… Our results indicate the presence of markers of MDR on MPs of stem-cell-like origin. Stem cells are a reservoir of P-gp-positive cells, the levels of which appear to correspond to disease progression,” the researchers pointed out.

Minimally invasive personalized liquid biopsy accounts for tumour heterogeneity characteristic of multisite tumour infiltrates, can detect the presence of MDR during routine follow-up, and allows for simultaneous analysis of disease burden, according to the researchers.

The test may be used as a complement to existing gold standard tests, supporting clinical staging criteria and streamlining easily into existing hospital workflows, they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

2 days ago
Case presentation: The patient is a 46-year-old Korean lady who first presented with aggravating pleuritic chest pain characterised by a stabbing pain in the chest when inhaling and exhaling. A diagnosis of non-small cell lung cancer (NSCLC) was made from computed tomography (CT)-guided needle aspiration biopsy, and the tumour was found to be epidermal growth factor receptor (EGFR) mutation-positive (exon 19 deletion). Chest imaging revealed the presence of left-sided pleural seeding nodules. The patient was treated with afatanib with partial response as best response. Ten months after starting treatment, the patient experienced disease progression.